Professor Ken Bradstock
BSc(med) MBBS PhD FRACP FRCPA
Professor Ken Bradstock was Chair of the Leukaemia Foundation’s Medical and Scientific Advisory Committee until August 2014, after he became a member at the inaugural meeting in April 2000. In November 2003, he became the Leukaemia Foundation’s National Medical Advisor and a member of the board.
A clinical haematologist at Westmead Hospital in Sydney, Professor Bradstock has had long-standing interests and involvement in clinical and laboratory research in hematological malignancies. Since 1981 he has been a Staff Specialist in Haematology and head of the Blood and Marrow Transplant Service at Westmead Hospital, and is also a Clinical Professor in the Department of Medicine at the University of Sydney.
He was chairman of the Australian Leukaemia Study Group from 1993-1999, and was the founding chairman of the Australasian Leukaemia and Lymphoma Group in 1999-2003. Currently, Professor Bradstock is Secretary of the Bone Marrow Transplant Society of Australia and New Zealand, and a member of the Scientific Advisory Committee of the Australian Bone Marrow Donor Registry.
Involved with the Leukaemia Foundation of Australia since 1997, Professor Bradstock has held such positions as National Medical Advisor and chairman of the Medical and Scientific Advisory Committee, as well as member of the Board of the Leukaemia Foundation. He is both a Trustee and chair of the Scientific Advisory Committee of the Anthony Rothe Memorial Trust, which provides research funding for haematological malignancies. He was chair of the Allogeneic Working Party of the BMT Network NSW, and Medical Director of that organization from 2002-2005. He was Secretary of the Haematology Society of Australia and New Zealand between from 1995-1999, and Co- ordinator of Advanced Training in Haematology during the same period. In October 2006, Professor Bradstock delivered the Carl de Gruchy Oration at the Annual Scientific meeting of the Haematology Society, in recognition of his contribution to the profession.
Professor Bradstock has over 25 years experience in the design and conduct of clinical trials, and has led the development of national trials in acute myeloid and lymphoblastic leukaemias. In laboratory science, his research interests have focused on the biology of acute lymphoblastic leukaemia (ALL), and in cellular immunotherapy in bone marrow transplantation.